<unk>  (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains<unk>  acetate, a progestin and ethinylestradiol, and, estrogen. It contains 17.4 mg ethinylestradiol and 103 mg<unk>  acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg<unk>  acetate per day. Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use. Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius. The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.
Segesterone acetate/ethinylestradiol
Ethinylestradiol/megestrol acetate
Norelgestromin/ethinylestradiol
Ethinylestradiol/drospirenone
Ethinylestradiol/levonorgestrel
Ethinylestradiol/cyproterone acetate
Ethinylestradiol/desogestrel
Ethinylestradiol/gestodene